Business Context and Reporting Period
Company: Molina Healthcare, Inc. (MOH)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Molina is a Fortune 500 managed healthcare provider serving approximately 5.5 million members across 21 states. The company operates primarily in government-sponsored programs: Medicaid, Medicare, and the Affordable Care Act (ACA) Marketplace. As of December 31, 2025, the company served 4.57 million Medicaid members, 262,000 Medicare members, and 655,000 Marketplace members.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Premium Revenue | $43,052 | $38,627 |
| Total Revenue | $45,426 | $40,650 |
| Medical Care Costs | $39,488 | $34,428 |
| Medical Care Ratio (MCR) | 91.7% | 89.1% |
| Operating Income | $781 | $1,707 |
| Net Income | $472 | $1,179 |
| Diluted EPS | $8.92 | $20.42 |
| Pre-tax Margin | 1.3% | 3.9% |
| Cash & Investments | $8.6 billion | $9.3 billion |
| Long-term Debt | $3.766 billion | $2.923 billion |
Material Changes vs. Prior Period
- Profitability Decline: Net income decreased 60% to $472 million, driven by a significant increase in the Medical Care Ratio (MCR) across all segments. The consolidated MCR rose 260 basis points to 91.7%, exceeding the company's long-term target range.
- Revenue Growth: Total revenue increased 12% and premium revenue increased 11%, fueled by the ConnectiCare acquisition (closed Feb 2025), Medicaid rate increases, and Marketplace membership growth.
- Membership Shifts: Total membership remained relatively flat at 5.5 million. Medicaid membership declined due to eligibility redeterminations, while Marketplace membership grew significantly (from 403k to 655k) due to product strategy and the ConnectiCare acquisition.
- Segment Performance:
- Medicaid: MCR increased to 91.8% due to higher utilization and acuity shifts outpacing rate increases.
- Medicare: MCR increased to 92.4% driven by higher-than-expected utilization in high-acuity dual-eligible populations.
- Marketplace: MCR increased to 90.6% from 75.4%, reflecting higher utilization relative to risk adjustment revenue and the impact of the ConnectiCare acquisition.
- Capital Actions: The company repurchased $1.0 billion of common stock in 2025 and issued $850 million in 6.500% Senior Notes due 2031 to refinance term loan debt.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Shift: In early February 2026, management announced an intent to exit the Medicare Advantage-Part D (MAPD) product for 2027 to focus exclusively on dual-eligible members. This is expected to result in an estimated pre-tax impairment charge of approximately $93 million in Q1 2026.
- Long-Term Targets: Despite near-term margin compression, the company maintains a long-term premium revenue growth target of 11% to 13% and a net income growth target of 11% to 13%.
- 2026 Expectations:
- Medicaid: Enrollment expected to be flat; modest contraction offset by new Florida Kids contract.
- Medicare: Enrollment expected to decrease ~12% to 230,000 members due to strategic MAPD exit.
- Marketplace: Enrollment expected to decrease to ~220,000 members, with premium revenue down ~50%, as the company repositions to restore target margins.
Key Risks and Contingencies
- Legislative Impact (OBBBA): The "One Big Beautiful Bill Act" (signed July 2025) is expected to reduce Medicaid Expansion enrollment by 15-20% (approx. 1.2 million members) by 2029 through work requirements and redeterminations. It also limits provider tax revenues starting in 2028.
- Medical Cost Trends: Elevated medical cost trends and utilization rates continue to outpace premium rate increases, creating a rate and trend imbalance.
- Contract Renewals: Significant concentration of revenue in California, Texas, New York, and Washington creates risk if contracts are not renewed or rates are insufficient.
- Cybersecurity: Ongoing risks related to data breaches, ransomware, and third-party vendor vulnerabilities.
- Legal Proceedings: Pending securities class action and shareholder derivative suits filed in late 2025 regarding earnings guidance disclosures.
Investor Verification Checklist
- MCR Sustainability: Verify if the 91.7% MCR is a temporary anomaly or a structural shift in cost trends versus reimbursement rates.
- MAPD Exit Impact: Confirm the timing and magnitude of the $93 million impairment charge and the operational impact of exiting MAPD in 2027.
- OBBBA Implementation: Monitor state-level implementation of the "One Big Beautiful Bill Act" to assess the actual timeline and magnitude of Medicaid enrollment reductions.
- Marketplace Margin Recovery: Assess the company's ability to restore Marketplace margins given the planned 50% revenue reduction in 2026.
- Debt Covenants: Review the amended Interest Coverage Ratio covenants (reduced to 1.75:1.00 for 2026) to ensure compliance given the lower net income.
- Legal Exposure: Track the status of the securities class action and derivative suits filed in late 2025.